Search research articles
Contact Us
Filters
Showing results (721-730 of 738) with videos related to
Page
of 74
Sort By:
Diabetes & Metabolism
|
February 16, 2022
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial
Jinlan Liao, Amy Kang, Chao Xia, et al.
Hypertension (Dallas, Tex. : 1979)
|
October 26, 2018
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
Robert M Carey, David A Calhoun, George L Bakris, et al.
Journal of the American Society of Nephrology : JASN
|
May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.
European Heart Journal
|
November 18, 2014
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial
David E Kandzari, Deepak L Bhatt, Sandeep Brar, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
February 23, 2021
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis
Meg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, et al.
European Journal of Heart Failure
|
May 10, 2026
Safety and Feasibility of the eLymTM System for Interstitial Decongestion in Acute Decompensated Heart Failure: Primary results of the DELTA-HF trial
Jorge Nuche, María Dolores García-Cosío Carmena, Jan Biegus, et al.
Journal of the American Society of Nephrology : JASN
|
August 13, 2016
BP Control and Long-Term Risk of ESRD and Mortality
Elaine Ku, Jennifer Gassman, Lawrence J Appel, et al.
The New England Journal of Medicine
|
April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Circulation
|
July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
American Heart Journal
|
June 4, 2014
Proceedings from Duke resistant hypertension think tank
Sreekanth Vemulapalli, Jamy Ard, George L Bakris, et al.
Page
of 74
Search research articles
Search
Showing results (721-730 of 738) with videos related to
Sort By:
Page
of 74
Diabetes & Metabolism
|
February 16, 2022
The impact of canagliflozin on the risk of neuropathy events: A post-hoc exploratory analysis of the CREDENCE trial
Jinlan Liao, Amy Kang, Chao Xia, et al.
Hypertension (Dallas, Tex. : 1979)
|
October 26, 2018
Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association
Robert M Carey, David A Calhoun, George L Bakris, et al.
Journal of the American Society of Nephrology : JASN
|
May 2, 2020
Renal, Cardiovascular, and Safety Outcomes of Canagliflozin by Baseline Kidney Function: A Secondary Analysis of the CREDENCE Randomized Trial
Meg J Jardine, Zien Zhou, Kenneth W Mahaffey, et al.
European Heart Journal
|
November 18, 2014
Predictors of blood pressure response in the SYMPLICITY HTN-3 trial
David E Kandzari, Deepak L Bhatt, Sandeep Brar, et al.
Clinical Journal of the American Society of Nephrology : CJASN
|
February 23, 2021
Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria: A CREDENCE Secondary Analysis
Meg Jardine, Zien Zhou, Hiddo J Lambers Heerspink, et al.
European Journal of Heart Failure
|
May 10, 2026
Safety and Feasibility of the eLymTM System for Interstitial Decongestion in Acute Decompensated Heart Failure: Primary results of the DELTA-HF trial
Jorge Nuche, María Dolores García-Cosío Carmena, Jan Biegus, et al.
Journal of the American Society of Nephrology : JASN
|
August 13, 2016
BP Control and Long-Term Risk of ESRD and Mortality
Elaine Ku, Jennifer Gassman, Lawrence J Appel, et al.
The New England Journal of Medicine
|
April 17, 2019
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg J Jardine, Bruce Neal, et al.
Circulation
|
July 12, 2019
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups
Kenneth W Mahaffey, Meg J Jardine, Severine Bompoint, et al.
American Heart Journal
|
June 4, 2014
Proceedings from Duke resistant hypertension think tank
Sreekanth Vemulapalli, Jamy Ard, George L Bakris, et al.
Page
of 74